Investigation of DNA medication passport for antidepressants in primary care.
Not Applicable
Recruiting
- Conditions
- <p>mild to moderate depression and anxiety disorders</p>10012375
- Registration Number
- NL-OMON27432
- Lead Sponsor
- Erasmus University Medical Center, Dept. Clinical Chemistry Dr. Molewaterplein 40, 3015 GD Rotterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 280
Inclusion Criteria
· =18 jaar
· eerste voorschrift N06A geneesmiddel (geen N06A geneesmiddel 1 jaar voor start N06A geneesmiddel)
Exclusion Criteria
geen CYP2C19 en CYP2D6 farmacogenetica test voorhanden of aangevraagd voor einde follow-up
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary objective of this study is to investigate if PGx-guided treatment with antidepressants (N06A drugs) for mild to moderate depression and/or anxiety disorders is improving therapy (less stops due to inefficacy or side effects) within the first 3 months after start treatment.</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary objectives are:<br /><br>· to monitor how often dose or drug adjustments are made after the PGx test is performed for antidepressants (exclusively analysed in intervention group)<br /><br>· to assess the implications of the PGx tests for other drugs<br /><br>· to assess what the consequence of PGx-guided treatment is on the trial-and-error treatment with antidepressants (N06A drug switches),<br /><br>· to assess what the consequence of PGx-guided treatment is on the referral to the secondary mental health care,<br /><br>· to determine if the PGx-guided antidepressants treatment before start therapy is cost-effective,<br /><br>· and retrospective analysis of primary and secondary objectives in control group,<br /><br>· retrospective analysis effect CYP3A4 on preterm stops, switches antidepressants and referral secondary mental health care</p><br>